Skip to content
thestock.space

Lactose (India) (BSE: LACTOSE) had a P/E of 18.9× on 6 Nov 2026, below the industry P/E of 28.7×, and the shares are 25% below their 52-week high. Sales and net profit grew 36% and 71% a year over 3 years, with ROCE of 14% and ROE of 9.8%. Debt is 0.96× equity. It is a small-cap company with a market cap of ₹129 Cr, ranked 111th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 6.8% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹105.00
Day high
₹105.00
Day low
₹101.35
Prev. close
₹105.35
Volume
3.6K

Health check

3 good · 2 fair · 1 to check
  • ReturnsBehind

    −6.8% over a year, better than 0 of 7 peers.

  • Price tagCheaper

    P/E 18.9 vs industry 28.7.

  • GrowthStrong

    Sales +36.0%, profit +71.2% a year over 3 years.

  • ProfitabilityAverage

    ROCE 14.4% vs peer median 17.9%.

  • Balance sheetFair

    Debt 0.96× equity, interest covered 2.8×, Piotroski 5 of 9.

  • Red flagsNone found

    No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹129 Cr, #111 of 154 in its industry by size.

Defensive

Beta 0.74 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹171 Cr · profit ₹7 Cr
Market cap
₹129 Cr
Small cap
P/E
18.9
Industry 28.7
Price to book
1.99
Peers 4.99
Dividend yield
0.00%
ROE
9.8%
Peers 14.7%
ROCE
14.4%
Peers 17.9%
Debt to equity
0.96
Debt ₹62 Cr
EPS (TTM)
₹5.41
OPM (TTM)
11.4%
Net margin 4.1%
Sales growth
+18.7%
Latest quarter vs a year ago
Profit growth
+57.9%
Latest quarter vs a year ago
Price to sales
0.75
EV/EBITDA 9.5

Strengths and risks

Strengths

  • Quarterly profit up 57.9% on a year ago.
  • Quarterly sales up 18.7% on a year ago.
  • P/E of 18.9 against an industry P/E of 28.7.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Lactose (India)

Lactose (India) Limited engages in the manufacture and trading of pharmaceutical products in India and internationally. The company offers lactose monohydrate; solid dosage forms comprising dry granulated, film, and lacquer coated tablets, as well as uncoated and blister packed solid dose forms; liquid dosage forms; and anhydrous and inhalation grade lactose. It also provides disaccharide lactulose, an active pharmaceutical ingredient that is used in the…

Headquarters
Mumbai
Sector
Healthcare
ISIN
INE058I01013
Website
lactoseindialimited.com

Price range

52 weeks

₹76.01₹136.45

Today

₹101.35₹105.00
Avg volume (3M)
10.1K
1-year return
minus 6.8%
From 52-week high
minus 25.0%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
LACTOSELactose (India)102.35minus 2.85%12918.91.9914.4%9.8%11.4%36.0%71.2%0.00%minus 6.8%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
39.641.236.845.847
35.135.933.740.740.9
4.55.33.156.1
11.3%12.8%8.3%11.0%12.9%
0.40.40.60.20.6
1.211.41.41.8
1.41.41.41.51.6
2.33.10.92.33.2
34.5%31.3%39.8%18.7%26.8%
1.52.20.51.92.4
1.161.670.411.451.88

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+36.0%
Profit CAGR 3Y
+71.2%
EPS CAGR 3Y
+69.5%
ROE
9.8%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
64.9114116163
–+75.3%+2.2%+40.4%
53.594.899.3145
11.4191718.4
17.5%16.7%14.6%11.3%
0.71.10.60.8
5.95.25.34.8
4.75.25.45.7
0000
1.59.76.98.6
17.5%29.7%25.4%29.7%
1.26.85.26.1
–+461.8%minus 24.0%+17.4%
0.965.394.064.68

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
12.612.612.612.6
2834.546.252.2
38.539.356.862.1
22.314.417.956.4
101101133183
56.155.363.969.3
–0.711.60.3
0000
0.71.54.50.5
44.543.253.5113
101101133183

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
7.98.7−0.35.6
−0.9−2.1−15.6−10.2
−8.3−5.718.80.7
−1.30.93−4
−1.6−2.2−14.4−10.5
6.36.6−14.7−4.9

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you